IMTX Stock Summary and Trading Ideas (Immatics N.V. - | NASDAQ:IMTX)

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Immatics N.V. - trades on the NASDAQ stock market under the symbol IMTX.

As of April 10, 2026, IMTX stock price declined to $10.43 with 185,011 million shares trading.

IMTX has a beta of 1.12, meaning it tends to be more sensitive to market movements. IMTX has a correlation of 0.07 to the broad based SPY ETF.

IMTX has a market cap of $1.40 billion. This is considered a Small Cap stock.

Last quarter Immatics N.V. - reported $23 million in Revenue and -$.34 earnings per share. This beat revenue expectation by $11 million and exceeded earnings estimates by $.14.

In the last 3 years, IMTX traded as high as $13.77 and as low as $3.30.

The top ETF exchange traded funds that IMTX belongs to (by Net Assets): KOMP, SPDW, CANC, SBIO, ONEQ.

IMTX has outperformed the market in the last year with a price return of +162.7% while the SPY ETF gained +30.9%. IMTX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +13.7% and +11.3%, respectively, while the SPY returned -1.8% and +7.2%, respectively.

IMTX support price is $10.28 and resistance is $11.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMTX shares will trade within this expected range on the day.